Investment Q&A

Q: There was an update on BNN stating that Jeffries added buy ratings to the 7 pot stocks tagged above. How would you rank these stocks and do you consider any of them a buy at current levels?

Q: I'm wondering whether you think this company is worth buying?

Thanks for your help

Q: What would your 4-5 favorite weed stocks be.
Thank you, keep up the excellent work.
PV

Q: May I please have your comments on the earnings for both companies. Thank you

Q: In mid-January you preferred trul over cura!
Has anything occurred over the last 4 months to change your preference?
Or would you prefer some other "weed" stocks.

Q: Your thoughts on these stocks. would you invest now and when are the earning for faf expected

Q: Could I get your opinion on these three stocks .
Thanks
Jim.

Q: Hello Peter,
Could you please comment on curaleaf's earnings and their reach into Europe? I would have thought their numbers and their global reach would have caused the stock to surge but it was tempered.. Also, given that US is not federally regulated, i thought US companies could not go international as I would have expected them to acquire outside USA at an earlier date. Any comments. Finally, since Curaleaf trades on cdnx, and if it is to move to Nasdaq or NYSE (with federal changes), what would happen to my shares. I know if it is TSXV to TSX or NYSE, it is non-issue. I just wanted clarity if shares traded on neo or cdnx, if same applies. Thanks very much.

Q: Hello Peter,
With the US elections and the senate win by the democrats, I was expecting that the US cannabis stocks would surge alot more than the Canadian ones. However, this is not the case and am wondering what that is.. For example. if you look at Aphria and Tilray, and Organirams, they have surged alot more than companies that are actually making money like Curaleaf in the USA .. Do you think this is because US companies are not surging as much due to them being on CDNX (not on TSX or NYSE) and may not be readily available for US investors..Also, can you comment on why Medmen is going through the roof in the last 5 days..? thanks very much

Q: which do you like best, or is a better stock in this space?

Q: Looking for growth companies to increase returns on my portfolio. I have chosen these four companies knowing fully well they can be volatile. Are there any reasons you wouldn't buy any one of them at these levels? My intention is to buy them as a 'growth basket'. If you think others might have more potential, please feel free to suggest them.

Q: The above positions are held by my daughter's trade account and I would like to transfer a few into her TFSA. Of these, what order would you do it in, aka rank?.......(For information purposes, she currently holds these US positions in her TFSA...PLTR, ROKU, TTD and VEEV in addition to a diverse group of Cdn positions.)......Please deduct extra credits!!!
........Many thanks for the wonderful advice...Tom

Q: Hi Peter and Staff

Aside from buying Alcanna at its high and selling it at its low, I have steered clear of the cannabis space as you and virtually all BNN Market Call guests have suggested.
I was surprised Brian Madden recently broke ranks and chuckled about it on BNN and picked this as a top pick.
It was the day of the last quarter or day before its release.
Where would you rank this in the cannabis space for money that you can afford to lose but would prefer not to

Thanks for all you do

Dennis

Q: Hello Peter,
Can you comment on curaleaf's earnings? This company has been doing well but it looks like the market did not like its current earnings yet the company is growing nicely. Also, why would a company remove the current CEO that has done quite well for the company? Any reason for the other three stocks: jwel well, and doc to be taking a hit. Is this just short term sector rotation due to the vaccine announcement and if so, is it better just to hold these for longer timeframe? Thanks very much.

Q: Hello Peter,
Recently the Canadian Cannabis companies surged for various reasons (short covering, and potential Biden win etc). However, I would have expected the US companies to have surged alot more given they are already operating in the US. Any comments? Also, would i better off allocating monies equally to HMMJ (Canada) and Hmus (US companies) or put more into Hmus? What is your opinion on Curaleaf?

Q: Hi Folks,

I'm looking for a mid-size company in the cannabis sector. Would you kindly rank, with a brief explanation, GTII, TRUL, CURA and VFF. OR do you have another name that you prefer?

Thanks,

Dennis

Q: Good day,
Your views please on this cannabis stock and on the purchase today which propelled the price 15% ?
Is it advisable to buy more in this high growth phase, or just how or sell ?

Thank you for being so helpful and efficient,

Jacques D.

Q: I am considering to take position in Canopy Growth stock. Please provide mi with 3 names of your suggestion and rank them initially from 1,2,3 with short why. Next question is where would be better to buy US or CAD stock. What is approx. % for start it position in portfolio at current time.
Andrew

Q: I'd like a suggestion for an undervalues Cannabis company. One that operates in Canada and/or the United States.
Thanks

Q: I am a trend-oriented investor (following momentum but with stop-losses on every position). When stock prove themselves, I like to keep them as long positions. This brings me my question re: CURA.CA. I have been finding the pot and petroleum sectors particularly lucrative since the start of the year. Among my pot holdings, I've got large position CURA.CA and was therefore pleased to see it rise 32% today on very high volume after announcing a partnership with the US's largest drugstore chain, CVS Health Corp, on a line of CBD products. CURA products are now sold in 8 states with more on the horizon. Also, at the start of the week, CURA announced a definitive agreement to acquire NV-based Acres Cannabis (Acres), for total consideration of $70m with $25m in cash, and $45m in equity. A recent GMP/FirstEnergy report has set a target of $21 on the share price and comments "We view CURA as having the broadest exposure amongst its closest peers to current or likely future MED to REC market conversions such as in MA, NY and NJ. This offers high torque growth opportunities for CURA as addressable market sizes can increase by ~5x–10x, while also providing a first-mover advantage (18+ months) to capture market share." So it would seem that the company has a long runway ahead with its increasing footprint in the retail sector.

Peter, could you provide your outlook for this stock? To me, it looks like it has a lot of traction. I only have a couple pot stocks that I treat as buy and hold; most, I am quite happy to sell when they have had a nice run until they consolidate again. Does this look like a buy-and-hold candidate?